Markers of intravascular coagulation and fibrinolysis in preeclampsia: Association with intrauterine growth retardation

Acta Obstetricia et Gynecologica Scandinavica

Volumn 76, Issue 6, 1997, Pages 541-546

  Schjetlein, Rune ^a   Haugen, Guttorm ^b   Wisløff, Finn ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Coagulation; Fibrinolysis; Intrauterine growth retardation; Preeclampsia

Indexed keywords

ANTITHROMBIN III; FIBRIN; FIBRIN MONOMER; MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; INFARCTION; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; PATHOGENESIS; PERFUSION; PLACENTA DISORDER; PREECLAMPSIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030981132     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.3109/00016349709024580     Document Type: Article

References (36)

1. Greer IA. Haemostasis and thrombosis in pregnancy. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and thrombosis. 3rd edn. Edinburgh: Churchill Livingstone, 1994: 987-1015.
2. Lindoff C, Lecander I, Åstedt B. Fibrinolytic components in individual consecutive plasma samples during normal pregnancy. Fibrinolysis 1993; 7: 190-4.
3. Persson BL, Holmberg L, Åstedt B, Nilsson IM. Coagulation and fibrinolysis in pregnancy complicated by intrauterine growth retardation. Acta Obstet Gynecol Scand 1982; 61: 455-9.
4. Sørensen JD, Secher NJ, Jespersen J. Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy. Acta Obstet Gynecol Scand 1995; 74: 257-61.
5. De Boer K, Ten Cate JW, Sturk A, Borm JJJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989; 160: 95-100.
6. Weenink GH, Treffers PE, Vijn P, Smorenberg-Schoorl ME, Ten Cate JW. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984; 148: 1092-7.
7. Estellés A, Gilabert J, España F, Aznar J, Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991; 165: 138-42.
8. Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S et al. Altered expression of plasminogen activator type I in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143-50.
9. Koh SCL, Anandakumar C, Montan S, Ratnam SS. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. Gynecol Obstet Invest 1993; 35: 214-21.
10. Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia. Br Med J 1971; 2: 12-16.
11. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-8.
12. Abitbol MM, LaGamma EF, Demeter E, Cipollina CM. Umbilical flow in the normal and pre-eclamptic placenta. Acta Obstet Gynecol Scand 1987; 66: 689-94.
13. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Much ado about nothing? Am J Obstet Gynecol 1990; 162: 311-16.
14. Halvorsen S, Skjønsberg OH, Godal HC. Thrombin treated plasma employed as a standard for determination of soluble fibrin. Thromb Res 1993; 72: 305-13.
15. Bjerkedal T, Bakketeig L, Lehmann EH. Percentiles of birth weights of single, live births at different gestational periods. Acta Pædiatr Scand 1973; 62: 449-57.
16. Gardner MJ, Altman DG. Statistics with confidence. Confidence-intervals and statistical guidelines. London: Br Med J 1989; 28-33.
17. Romero R, Lockwood C, Oyarzun E, Hobbins JC. Toxemia: New concepts in an old disease. Sem Perinat 1988; 12: 302-23.
18. Trofatter KF Jr, Howell ML, Greenberg CS, Hage ML. Use of the fibrin D-dimer in screening for coagulation abnormalities in preeclampsia. Obstet Gynecol 1989; 73: 435-9.
19. Cadroy Y, Grandjean H, Pichon J, Desprats R, Berrebi A, Fournié A et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993; 100: 416-20.
20. Weenink GH, Kahlé LH, Lamping RJ, Ten Cate JW, Treffers PE. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 1984; 63: 57-61.
21. Bremme K, Östlund E, Almqvist I, Heinonen K, Blombäck M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80: 132-7.
22. Nolan TE, Smith RP, Devoe LD. Maternal plasma D-dimer levels in normal and complicated pregnancies. Obstet Gynecol 1993; 81: 235-8.
23. Aznar J, Gilabert J, Estellès A, España F. Fibrinolytic activity and protein C in preeclampsia. Thromb Haemost 1986; 55: 314-17.
24. Ho C-H, Yang Z-L. The predictive value of the hemostasis parameters in the development of preeclampsia. Thromb Haemost 1992; 67: 214-18.
25. Kessler CM, Bell WR. The effect of homologous thrombin and fibrinogen degradation products on fibrinogen synthesis in rabbits. J Lab CHn Med 1979; 93: 768-82.
26. Thorburn J, Drummond MM, Whigham KA, Lowe GDO, Forbes CD, Prentice CRM et al. Blood viscosity and haemostatic factors in late pregnancy, pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1982; 89: 117-22.
27. Beller FK, Ebert Ch, Dame WR. High molecular fibrin derivates in pre-eclamptic and eclamptic patients. Eur J Obstet Gynecol Reprod Biol 1979; 9: 105-10.
28. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1464-72.
29. 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-6.
30. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994; 101: 488-92.
31. Neiger R, Trofatter MO, Trofatter KF Jr. D-dimer test for early detection of HELLP syndrome. South Med J 1995; 88:416-19.
32. Kelton JG, Hunter DJS, Neame PB. A platelet function defect in preeclampsia. Obstet Gynecol 1985; 65: 107-9.
33. Pekonen F, Rasi V, Ämmälä M, Viinikka L, Ylikorkala O. Platelet function and coagulation in normal and preeclamptic pregnancy. Thromb Res 1986; 43: 553-60.
34. Sibai BM, Taslimi MM, El-Nazer A, Amon E, Mabie BC, Ryan GM. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol 1986; 155: 501-9.
35. Sibai BM, Mohammed K, Ramadan K, Usta I, Salama M, Mercer BM et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169: 1000-6.
36. Poldre PA. Haptoglobin helps diagnose the HELLP syndrome. Am J Obstet Gynecol 1987; 157: 1267.